Trade Name: Ortho Evra

Generic Name: norelgestromin/ethinyl estradiol transdermal system

Sponsor: Ortho-McNeil Pharmaceutical, Inc.

Approval Date: March 04, 2002

Indications: For the prevention of pregnancy.
Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Item</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td></td>
</tr>
<tr>
<td>Approvable Letter</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td></td>
</tr>
<tr>
<td>Summary Review</td>
<td></td>
</tr>
<tr>
<td>Officer/Employee List</td>
<td></td>
</tr>
<tr>
<td>Office Director Memo</td>
<td></td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
<td></td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Environmental Assessment</td>
<td></td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology/Biopharmaceutics Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
<td></td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
<td></td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td>X</td>
</tr>
</tbody>
</table>
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
21-180/S-001

APPROVAL LETTER
Dear Ms. Panasewicz:

Please refer to your supplemental new drug application dated January 31, 2002, received February 1, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for ORTHO-EVRA™ (norelgestromin/ethinyl estradiol transdermal system).

This "Prior Approval" supplemental new drug application provides for a change in the release rate acceptance criteria at the 24-hour time point.

We have completed the review of this supplemental application, and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Jennifer Mercier, B.S., Regulatory Project Manager, at (301) 827-4260.

Sincerely,

[See appended electronic signature page]

Moo-Jhong Rhee, Ph.D.
Chemistry Team Leader, for the
Division of Reproductive and Urologic Drug Products,
(HFD-580)
DNDC II, Office of New Drug Chemistry
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Moo-Jhong Rhee
3/4/02 03:54:14 PM
APPLICATION NUMBER:
21-180/S-001

CHEMISTRY REVIEW(S)
DIVISION OF REPRODUCTIVE AND UROLOGIC DRUG PRODUCTS
REVIEW OF CHEMISTRY MANUFACTURING AND CONTROLS
CHEMIST'S REVIEW #1

1. NDA NUMBER: 21-180

2. NAME AND ADDRESS OF APPLICANT
Johnson & Johnson Pharmaceutical Research & Development LLC
920 Route 202 South
Raritan, NJ 08869-0602

3. SUPPLEMENT NUMBER/DATE/DATE ASSIGNED
SCS-001/1-31-02/2-01-02

4. NAME OF THE DRUG: ORTHO EVRA

5. NONPROPRIETARY NAME: Norelgesrtomin/Ethinyl estradiol Transdermal Drug Delivery System

6. SUPPLEMENT PROVIDES FOR: A change in the release rate acceptance criteria at the 24-hour time point

7. AMENDMENTS/REPORTS/ DATE: None

8. PHARMACOLOGICAL CATEGORY
Combination estrogen/progestin, prevention of pregnancy.

9. HOW DISPENSED
Prescription

10. RELATED IND/NDA/DMF/SUPPLEMENT
None

11. DOSAGE FORM: Transdermal

12. POTENCY
Norelgestromin/Ethinyl estradiol (6.0 mg/0.75 mg per 20 cm²) delivering 150 μg norelgestromin, and 20 μg ethinyl estradiol per day.

13. CHEMICAL NAME AND STRUCTURE
Norelgestromin - (17\(\alpha\))-17-hydroxy-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one-3-oxime
Ethinyl estradiol - 19-Norpregna-1,3,5(10)-trien-20-yn-3,17-diol, (17\(\alpha\))

![Chemical structures of Norelgestromin and Ethinyl estradiol]

Ethinyl estradiol  
Molecular wt: 296.40  

Norelgestromin  
Molecular weight: 327.47

14. COMMENTS
The acceptance criterion for release rate at 24 hour was proposed to be changed based on the data from the production lots, and extrapolated 24 hours release rate from the clinical lots.

15. CONCLUSIONS AND RECOMMENDATIONS:
The supplement may be approved with respect to CMC. Please issue an approval letter.

Reviewed By:  Amit K. Mitra, Ph.D, 2-28-02

R/D INIT. BY:  Moo-Jhong Rhee, Ph.D  

CC:  A. K. MITRA/HFD-580  
M.J.RHEE/HFD-580  
J. Mercier/HFD-580  
NDA 21-180
Redacted ___ page(s)
of trade secret and/or
confidential commercial
information from
Chemistry Review
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Amit K. Mitra  
3/1/02 04:15:50 PM  
CHEMIST

Moo-Jhong Rhee  
3/4/02 10:01:54 AM  
CHEMIST  
I concur
APPLICATION NUMBER:
21-180/S-001

CLINICAL PHARMACOLOGY AND
BIOPHARMACEUTICS REVIEW(S)
ORTHOV/ EVRA was approved by the Agency in Nov, 2001. The interim dissolution specifications for this transdermal product were set (based on the available data on the clinical trial formulations) at 0.5 hr, 2 hr, 8 hr and 24 hr time points (the 24 hr time point was added by the Agency). Please refer to original CPB review on NDA 21-180 for our proposed dissolution specifications.

In this prior-approval supplement, additional data was sent in by the sponsor on dissolution (individual data on all the production batches). The sponsor is currently proposing that the 24-hour specification be changed to > % for NGMN and > % for EE. The following were the statistics computed from the data submitted on the 24 hour time point (for all production batches):

<table>
<thead>
<tr>
<th></th>
<th>EE</th>
<th>NGMN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>73.9</td>
<td>71.4</td>
</tr>
<tr>
<td>SD</td>
<td>4.5</td>
<td>3.5</td>
</tr>
<tr>
<td>Minimum</td>
<td>[    ]</td>
<td>[    ]</td>
</tr>
<tr>
<td>Maximum</td>
<td>[    ]</td>
<td>[    ]</td>
</tr>
</tbody>
</table>

The proposed change (as mentioned above) is acceptable to OCPB. The following went into consideration while arriving at this decision:

1) In absence of IVIVC, a ± % (FS dissolved) was allowed on the overall means at different time points. Therefore, at the 24 hr time point the specifications are, not less than % (for EE) and % (for NGMN).
2) Review of the data initially submitted to the NDA indicated that it takes ~ 96 hours for >9% dissolution of NGMN and EE.

3) A modeling analysis in which the sponsor projected the 24 hour dissolution profile of the phase 3 clinical batches (note: 24 hr. dissolution data for the clinical batches were not determined since it was not in the original specifications) show that around 4% FS dissolved was the lowest value (among the 3 clinical batches) at 24 hr for NGMN and EE, and this provides additional justification for approving specifications at 24 hours no less than 9% for either.

The above was discussed with Dr. Malinowski (Director, DPE 2 on 2/20/02), Dr. Parekh (TL), and in a meeting with the CMC team and Jen Mercier (PM) on 2/22/02.

Based on the analysis of complete data submitted by the sponsor post-approval, the following should be the dissolution specifications for ORTHO EVRA:

<table>
<thead>
<tr>
<th>% FS for NGMN</th>
<th>% FS for EE</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5 hr</td>
<td>2.0 hr</td>
</tr>
<tr>
<td>&lt;9%</td>
<td>&lt;9%</td>
</tr>
</tbody>
</table>

Comments to the Sponsor:

The sponsor is hereby reminded again to submit data justifying choice of the current dissolution medium (eg. how would the dissolution profile/results appear using conventional aqueous media, or that containing a or , or containing lower concentrations of ).
This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.

/s/
-----------------------------
Dhruba Chatterjee
2/25/02 02:55:16 PM
BIOPHARMACEUTICS
Current diss. spec. proposal acceptable

Ameeta Parekh
2/25/02 04:09:02 PM
BIOPHARMACEUTICS
I concur
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
21-180/S-001

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS
Dear Ms. Panasewicz:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for ORTHO EVRA™ (norgestromin/ethynyl estradiol) Transdermal Patch.

You were notified in our letter dated February 14, 2002 that your supplemental application was not accepted for filing due to non-payment of fees. This is to notify you that the Agency has received all fees owed and your supplemental application has been accepted as of February 14, 2002.

Unless we notify you within 60 days of the above date that the application is not sufficiently complete to permit a substantive review, this application will be filed under section 505(b) of the Act on April 14, 2002 in accordance with 21 CFR 314.101(a).

If the application is filed, the primary user fee goal date will be August 14, 2002

Please cite the NDA number listed above at the top of the first page of any communications concerning this application. All communications concerning this NDA should be addressed as follows:

U.S. Postal Service/Courier/Overnight Mail:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Reproductive and Urologic Drug Products
Attention: Division Document Room, 17B-20
5600 Fishers Lane
Rockville, Maryland 20857

If you have any questions, contact Jennifer Mercier, Regulatory Project Manager, at (301) 827-4260.
Sincerely,

Terri Rumble, B.S.N.
Chief, Project Management Staff
Division of Reproductive and Urologic Drug Products; HFD-580
Office of Drug Evaluation III
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Jeanine Best
2/14/02 02:10:23 PM
Signing for Terri Rumble
Dear Ms. Panasewicz:

We have received your supplemental new drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: ORTHO EVRA™ (noregestromin/ethinyl estradiol) Transdermal Patch

NDA Number: 21-180

Supplement number: S-001

Date of Application: January 31, 2002

Date of receipt: February 1, 2002

We note that you are in arrears for payment of fees for products, or establishments, or previously submitted applications.

Because an application is considered incomplete and cannot be accepted for filing until all fees owed have been paid, review of the application referenced above may not begin at this time. Upon receipt of the outstanding fees, we will start the user fee clock and commence review of your application. Payment should be submitted to the following address:

Food and Drug Administration
P.O. Box 360909
Pittsburgh, PA 15251-6909

Checks sent by a courier should be addressed to:
NOTE: This address is for courier delivery only. Make sure the FDA Post Office Box Number (P.O. Box 360909) and user fee identification number are on the enclosed check.

Please cite the application number listed above at the top of the first page of any communications concerning this application. All communications concerning this supplement should be addressed as follows:

U.S. Postal Service: Courier/Overnight Mail:
Center for Drug Evaluation and Research
Division of Reproductive and Urologic Drug Products, HFD-580
Attention: Division Document Room, 17B-20
5600 Fishers Lane
Rockville, Maryland 20857

If you have any questions, contact Jennifer Mercier, Regulatory Project Manager, at (301) 827-4260.

Sincerely,

Terri Rumble, B.S.N.
Chief, Project Management Staff
Division of Reproductive and Urologic Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Jeanine Best
2/14/02 11:50:46 AM
Signing for Terri Rumble
NDA 21-180

PRIOR APPROVAL SUPPLEMENT

Johnson & Johnson Pharmaceutical Research & Development
Attention: Donna Panasewicz
Senior Director, Regulatory Affairs
920 P.O. Box 300
Raritan, NJ 08869-0602

Dear Ms. Panasewicz:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: ORTHO EVRA™ (noregestromin/ethinyl estradiol) Transdermal Patch

NDA Number: 21-180

Supplement number: s-001

Date of supplement: January 31, 2002

Date of receipt: February 1, 2002

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, this application will be filed under section 505(b) of the Act on April 1, 2002 in accordance with 21 CFR 314.101(a).

All communications concerning this supplement should be addressed as follows:

U.S. Postal Service/Courier/Overnight Mail:
Center for Drug Evaluation and Research
Division of Reproductive and Urologic Drug Products, HFD-580
Attention: Division Document Room, 17B20
5600 Fishers Lane
Rockville, Maryland 20857
If you have any question contact me at (301) 827-4260.

Sincerely,

Jennifer Mercier  
Regulatory Project Manager  
Division of Reproductive and Urologic Drug Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Jennifer L. Mercier
2/5/02 12:09:36 PM